Proactive Investors - Run By Investors For Investors

Alliance Pharma unveils big board reshuffle with deputy CEO to become CEO, and a new chairman

The AIM-listed speciality pharmaceutical group said Peter Butterfield, currently deputy CEO, will take over from John Dawson as CEO on 1 May 2018
Boardroom
It added that Dawson, who founded Alliance in 1996, will remain on the board as a non-executive director

Alliance Pharma PLC (LON:APH) has unveiled the succession of its deputy CEO to CEO, the current CEO's transition to a non-executive role, and the appointment of a new chairman.

In a statement, the AIM-listed speciality pharmaceutical group said Peter Butterfield, currently deputy CEO, will take over from John Dawson as CEO on 1 May 2018.

READ: Alliance Pharma brings on board its third international product with US$17.5mln Vamousse deal

It added that Dawson, who founded Alliance in 1996, will remain on the board as a non-executive director.

Alliance Pharma also announced that following a search process involving internal and external candidates, as of today, David Cook - a non-executive director of the company for almost four years - will take over as its non-executive chairman from Andrew Smith, who will step down from Alliance's board. 

Cook is a chartered accountant who worked in a professional practice for 13 years with PwC, following which he has worked for 14 years in the pharmaceutical industry, including having roles at EUSA Pharma Inc, Jazz Pharmaceuticals Ltd and Biotie Therapies Corporation. He is currently chief financial officer of Ellipses Pharma Limited.

Close collaborations

Commenting on the Board changes, John Dawson said: "Peter Butterfield and I have worked closely together since he joined Alliance following our acquisition of Cambridge Laboratories eight years ago.

“His career path has been impressive and his capabilities give the Board the utmost confidence that, as CEO, Peter will be highly effective in driving the Company forward.”

The outgoing CEO added: "David Cook has been an invaluable Board member over the past four years and we are delighted that he has agreed to chair the Board as the Company continues on its growth trajectory.”

Butterfield, Alliance's Deputy CEO, commented: "I am delighted to be taking on the leadership of Alliance as it continues to grow. It has been a real pleasure working alongside John and I'm very pleased that he has decided to continue his involvement with the Company as a non-executive director."

In late afternoon trading, Alliance Pharma shares were off 0.7% at 67.2p.

 -- Adds share price --

View full APH profile View Profile

Alliance Pharma plc Timeline

Related Articles

pills
July 25 2018
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions
pills
November 07 2018
'I joke that Wall Street and Big Pharma didn't wake up today wondering where that next $10 million Canadian product is going to come from, but we do,' says CEO Doug Janzen
1528098797_Biotech-lab.jpg
June 04 2018
While tricky, the last year has seen Abzena increase its customer engagement with its integrated discovery, development and manufacturing service offering

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use